1. 斑塊性乾癬：Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
2. 膿泡性乾癬：Pustular psoriasis in adult patients for systemic therapy.
3. 乾癬性關節炎：Psoriatic arthriti patients who have failed to respond or resistant to disease-modifying antirheumatic drug(DMARD) <20210122>
4. 活動性僵直性脊椎炎 <20220721>
#仿單變更2021 #仿單變更2022

Anti-interleukin 17-Receptor Antibody; Antipsoriatic Agent; Monoclonal Antibody

Distribution: Vd: 8.9 ± 9.4 L
Metabolism: Degraded into small peptides in a manner similar to endogenous IgG
Bioavailability: SubQ: ~55%
Time to peak: ~3 days
Excretion: Clearance: Mean (±SD) apparent total clearance (CL/F) of a 210 mg subcutaneous dose was 3.0 ± 3.5 L/day

Crohn disease (In some studies, exacerbation of Crohn disease was observed with brodalumab)

1. The lowest exposure would be expected during the period of organogenesis.
2. The American Academy of Dermatology considers brodalumab for the treatment of psoriasis to be likely acceptable for use in male patients planning to father a child (AAD-NPF [Menter 2019]).

It is not known if brodalumab is present in breast milk.(Should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.)

Infection (25%; including bronchitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, urinary tract infection), suicidal ideation, neutropenia, antibody development <20210122>

SubQ: 210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks.
Consider discontinuing if an adequate response is not achieved after 12 to 16 weeks (continuing treatment beyond 16 weeks in patients without an adequate response is not likely to result in greater success).

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).